LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis
Conditions
Psoriasis
Trial Timeline
Dec 1, 2009 → Aug 1, 2010
NCT ID
NCT01018810About LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous is a phase 2 stage product being developed by Eli Lilly for Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01018810. Target conditions include Psoriasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01018810 | Phase 2 | Terminated |
Competing Products
20 competing products in Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| Ixekizumab | Eli Lilly | Phase 3 | 77 |
| 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Baricitinib | Eli Lilly | Phase 2 | 52 |
| CT-P43 + Stelara | Celltrion | Phase 3 | 77 |
| CT-P17 + EU-approved Humira | Celltrion | Phase 3 | 77 |
| CT-P55 + EU-approved Cosentyx | Celltrion | Phase 3 | 77 |
| AMG 139 | AstraZeneca | Phase 1 | 33 |
| alefacept + polyvalent pneumococcal vaccine | Astellas Pharma | Approved | 85 |
| alefacept | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus Cream | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Phase 3 | 77 |
| peficitinib + Placebo | Astellas Pharma | Phase 2 | 52 |
| Alefacept | Astellas Pharma | Phase 3 | 77 |
| Amevive exposure | Astellas Pharma | Pre-clinical | 23 |
| alefacept + placebo | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Approved | 85 |
| ASKP1240 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus Cream | Astellas Pharma | Phase 3 | 77 |